Alyeska Investment Group
CBMG

Alyeska Investment Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Alyeska Investment Group’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,000
Closed -$865K – 547
2019
Q1 		$865K Buy
+50,000
New +$908K 0.01% 324

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Alyeska Investment Group's CBMG Position: Q2 2019 in Review

Alyeska Investment Group sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2019, closing a stake of 50,000 shares — an estimated $865K sold.

Alyeska Investment Group first reported a position in CBMG in Q1 2019 and held it in 1 quarter. The position peaked at $865K in Q1 2019. 40 funds tracked by Wall St. Rank hold CBMG as of Q2 2019.

  • Alyeska Investment Group reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 Cellular Biomedicine Group, Inc. shares in Q2 2019, an estimated $865K.
  • Alyeska Investment Group first reported a position in Cellular Biomedicine Group, Inc. in Q1 2019 and held it in 1 quarter.
  • Alyeska Investment Group's Cellular Biomedicine Group, Inc. position peaked at $865K in Q1 2019.
  • 40 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2019.

Based on Alyeska Investment Group's 13F filing for Q2 2019, filed 14 Aug 2019.